Angela Rossetti, an Independent Director, Resigned from the Board of Directors of Palatin Technologies, Inc. and as A Member of the Company’s Audit Committee and Nominating and Corporate Governance Committee
December 18, 2020 at 04:31 pm EST
Share
On December 17, 2020, Angela Rossetti, an independent director, resigned from the Board of Directors of Palatin Technologies, Inc. and as a member of the company’s Audit Committee and Nominating and Corporate Governance Committee (the NCG Committee). The resignation of Ms. Rossetti was not due to a disagreement with the company on any matter relating to the company's operations, policies, or practices.
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also engaged developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. It has completed Phase III PL9643 clinical study for dry eye disease. It is also conducting Phase II study of oral PL8177 in patients with ulcerative colitis.
Angela Rossetti, an Independent Director, Resigned from the Board of Directors of Palatin Technologies, Inc. and as A Member of the Company’s Audit Committee and Nominating and Corporate Governance Committee
PALATIN TECHNOLOGIES, INC. 
